enzyme preparations. A monoclonal antibody was raised against the liver enzyme and a specific antiserum against the erythrocyte enzyme. The monoclonal antibody (EP-2) recognized prolidase from erythrocytes and liver, in equal proportions. 'The antiserum also recognized the enzyme from erythrocytes and liver. Immunoprecipitation studies with these antibodies suggested only a single species of prolidase in erythrocytes and liver. Using an immobilized monoclonal antibody (EP-2) as an immunoadsorbent, prolidase was partially purified from crude extracts, and the protein of the partially purified enzyme was identified by immunoblotting using antiserum. A protein band with a MW = 56,000 was demonstrated specifically when crude extracts from the liver and erythrocytes were examined using NaDodS04/acrylamide gel electrophoresis. l'he subunit protein was absent in erythrocytes from a patient with prolidase deficiency. We propose that the absence of the subunit is one cause of the prolidase deficiency. (Pediatr Res 22: 627-633, 1987) Abbreviations activity in blood cells had no clinical abnormalities. whereas his brother, who had the same deficiency. had typical clinical features (3) .
The properties of prolidase froni mammals. including hunians. have been reported (4-1 1). Most of the evidence obtained indicates that prolidase is a ubiquitous enzyme the substrate specificity of which is restricted to imidopeptides (7. 9, 10). Ilowevcr. the knowledge of human prolidase is limited and an imrnunological analysis of the human enzyme with a specific antibody has apparently not been reported. The nature of the prolidase mutation is poorly understood.
T o begin to address some of these problems. we designed improved method for purifying the enzyme. Using a highly purified preparation. we prepared monoclonal and polyclonal antibodies directed against human prolidase and demonstrated the subunit of prolidase in crude extracts of the liver and crythrocytes. In addition. we noted the absence of the subunit in a patient with prolidase deficiency.
EXPERIMENTAL PROCFDlJRES
.\frrtc~r.iol.s. Bacterial protcin A adsorbent was ohtrlincd ti-om Kaketsukcn Co. Ltd. (Kurnanioto. Japan). CNBr-activated Sepharose 4B was purchased J'rom Pharmacia Fine Chemicals (LJppsala. Sweden). Glycyl-I.-proline was a product of I'eptidc Kescarch Institute (Osaka. Japan). Affiniity purilicd goat antinlouse 1,gG IIPI,C, high performance liquid chromatography was purchased from Jackson Irnmuno Research t.aboratorics. 3.4 .13.9) splits imidodipep-natant that was obtained by centrifugation at 500 X ,t7 for 10 mi11 tides with C-terminal proline or hydroxyproline residues. In and then 15,000 X g for 20 min was fractionated by amnionium humans, prolidase activity that is absent or markedly decreased sulfate (40-60%). The precipitate was suspended in buffer A results in prolidase deficiency, a genetic disease transmitted (made by mixing equal volumes of 20 m M Tris-HCI, pH 7.4. through autosomal recessive inheritance ( I). This defect has been and 4 mM sodium phosphate buffer. pH 7.4) and dialyzed associated with mental retardation, imidodipeptiduria, and in extensively against the same buffer. The dialysate was applied to some instances, deep skin ulcers (2) . It is known that the clinical a hydroxyapatite column (2.6 X 50 cm). previously cquilibratcd featurcs ofthe disease vary from family to family and even within with buffer A. The column was washed with buffer A and a family (2) . In one instance, a man with an absence of prolidase prolidase was eluted with the buffer. as a broad peak. The fraction containing the enzyme was applied to a column of DEAE to ion exchange (Mono Q 5/20, Pharmacia Fine Chemicals) and then to gel filtration (Superose 12, Pharmacia Fine Chemicals), which were run in an HPLC system (Pharmacia Fine Chemicals). The prolidase was eluted from the Mono Q column with a salt gradient from 100 to 500 mM of Tris-HC1 buffer, pH 8.0. The fraction containing the enzyme was fractionated by Superose in 50 mM Tris-HC1 buffer, pH 8.0. Rechromatography on the Mono Q column usually resulted in two peaks of proteins, the earlier of which possessed prolidase activity. The final preparation is shown in Figure 1 .
Purrfication ofprolidase from erythrocytes. When we analyzed the enzyme prepared using a previously described method (9), several protein peaks were seen on the HPLC. We then used the following method: washed erythrocytes (from 200 ml whole blood) were hemolyzed by freezing and thawing, and the hemolysate was centrifuged at 15,000 x g for 10 min. The supernatant was diluted with 50mM Tris-HCI (four times) and mixed with DEAE cellulose preequilibrated with 50 mM Tris-HCI, pH 7.4 (50 g of DE52 for 200 ml whole blood). The mixture was stirred gently for 4 h at 4" C, and the residue was packed in a column (7 cm in diameter). The column was washed with 50 mM Tris-HCI buffer and the prolidase was eluted with 350 mM Tris-HCI buffer, pH 7.4. As described for the liver enzyme, the eluate was subjected to ammonium sulfate fractionation, hydroxyapatite column chromatography (4 x 15 cm for 200 ml whole blood) and HPLC. Similar purification as that for the liver enzyme was obtained by HPLC; however, sometimes closely related proteins caused contamination. In that case even further rechromatographies with low recovery rates were required. Production of monoclonal antibody. Highly purified liver prolidase was used to immunize a BALB/c female mouse by intraperitoneal administration of about 25 pg protein emulsified in Freund's complete adjuvant (Difco Laboratories, Detroit, MI). The mouse was reimmunized 2 wk later with 25 gg of protein given intravenously, and 3 days later the spleen was removed. Spleen cells (I x lo8) and P3U-I myeloma cells (5 x lo7) were fused in the presence of polythylene glycol (12) (MW = 4000; Sigma Co. Ltd., St. Louis, MO). The fused cells were incubated with HAT medium for 10 days in a C 0 2 incubator and then The gradient started at 100 mM Tris-HC1 buffer, pH 8.0, and ended at 500 mM of the same buffer. The column was washed with 5 ml of 10 mM Tris-HC1 buffer prior to start of the gradient. Flow rate was 1 ml/min. Enzyme activity existed with the peak. replaced in hypoxanthine thymidine medium. The clones were tested for the production of antibody to human liver prolidase as follows. The wells of a polyvinyl microplate (96-well immunoplate, Nunc) were coated with antimouse IgG (5 pg/ml in 0.1 M carbonate buffer, pH 8.5) and left overnight at 4" C. After washing the wells three times with 10 mM sodium phosphate buffer, pH 7.4, containing 150 mM NaCl (PBS), 50 pl of the culture supernatant was added and the mixture then incubated at 37" C for 2 h. The supernatant was removed and after three washings with PBS, 100 pl of a solution containing approximately 30 m u of prolidase was added. The solution was prepared as follows: human liver obtained at autopsy was homogenized in a 10-fold volume of 50 mM Tris-HCI buffer, pH 7.4. The homogenate was centrifuged at 15,000 x g for 20 min, the supernatant was mixed with 5% bovine serum albumin in PBS, and the enzyme activity was adjusted to 30 mU/ml. Incubation was continued for 2 h at 37" C or overnight at 4" C. The solution was then removed and the wells were washed three times with PBS. This was followed by incubation with 100 p1 of 2 mM glycyl-Lproline in 50 mM Tris-HC1 buffer, pH 7.4, containing 5 mM MnCI2. Incubation was carried for 4 h at 37" C, and at the end of incubation 100 of acid ninhydrin solution prepared according to the description of Chinard were added. The plate was heated at 90-95" C for 15 min to determine the amount of Lproline released from glycyl-L-proline, after which the absorbance at 495 nm was recorded.
Controls for nonspecific binding were included by omitting either the goat antimouse IgG or the culture supernatant. Less than 0.01 of absorbance was recorded under these conditions. Several clones gave strongly positive responses with optical densities above 0.2. These responses suggested that the culture supernatants included antibody to human liver prolidase. The cloned plaques which gave a positive response were selected and recloned several times in hypoxanthine thymidine medium by limiting dilution (14). Finally, the cell line used in the present study was established. The immunoglobulin (designated EP-2) produced by this clone was found to be of the immunoglobulin subclass IgG,. The hybridoma cells were grown as an ascites form by intraperitoneal injection into pristane-treated mice (14) and the resulting ascites fluid was used as a source of monoclonal antibody after removal of cells by centrifugation at 1000 x g for 10 min. The IgG was purified from the ascites fluid by ammonium sulfate precipitation and ion exchange column (Mono Q column) equipped with an HPLC system (Pharmacia).
Preparation of antiserum. Antiserum was produced in a rabbit by injections of protein in Freund's adjuvant (Difco). The injection schedule was as follows: 100 pg of human erythrocyte prolidase was injected into the lymphnodes of the hind limbs (15), followed by 100 pg subcutaneous booster injections at 2-wk intervals. The antiserum was used for further experiments without any treatment. A single precipitation line was seen on Ochterony's plate, when the antiserum was analyzed with purified erythrocyte enzyme.
Preparation of immobilized IgG (EP-2).
Purified IgG (EP-2) as described above was extensively dialyzed against 0. I M sodium phosphate buffer, pH 7.4 containing 0.5 M NaCI. CNBr-activated Sepharose 4B was reconstituted and washed according to the manufacturer's instructions. It was then coupled with the EP-2 antibody through overnight incubation at 4" C with the antibody (0.3 mg of proteinlml of gel) in 0.1 M sodium phosphate buffer, pH 7.4, containing 0.5 M NaCI. Approximately 95% of the antibody was coupled to the Sepharose.
Affinity purification ofproliduse from crude extracts. Postmortem specimens of liver, kidney, small intestine, and blood from control subjects with normal prolidase activity were used. Screening for variant forms of prolidase (16) had not previously been done. Tissues were routinely homogenized (0.1 g wet weight per ml) in 50 mM Tris-HCI buffer, pH 7.4 phenylmethyl sulfonyl fluoride (1 mM), benzamidine hydrochloride (2 mM), using a glass Teflon homogenizer. The homogenates were centrifuged at HUMAN PROLIDASE AND PROLIDASE DEFICIESC'Y 500 x g for 10 min and the supemitants at 15.000 x g for 20 min. Thc resulting supernatants wcrc mixed with appropriate a amounts of suspension of EP-2 imrnobililcd Scpharosc 4B (30-b 40 gel). The mixtures (0.5-3 ml) were incubated at room temperature for 2 h or at 4" C' for 6 h. Afier incubation. the gel was precipitated by brief'centrilugatio~i and washcd three times with 1.5 ml icc cold 50 mM Tris-HC1 b u f i r . pH 7.4. The final gel precipitate was mixcd with 150 62.5 mM Tris HCI bufkr. pH 6.8, containing 4% NaDodS04, 4% mercaptoethanol, and 10% glycerol. The resulting suspensions werc boiled at 100" C for I min. After precipitation of the gel, 100 of supernatant was used for gel electrophoresis.
Erythrocytes were separatcd from whole blood by centrifugation and washcd three times with ice cold 150 mM NaCI. The crude hemolysate was prepared by freezing and thawing the packed crythrocytcs. The supernatant of thc crude hemolysate after centrifugation at 15,000 x for 5 min was uscd as a crude extract. Affinity purification of prolidasc from the erythrocytes was carried out as described above.
Imrnuno~)r(~cij)i/u/ion .s/itdic~.s. Crude tissue extracts were incubated for 2 h at 24" C with the monoclonal antibody or antiserum, followed by S / u~~l~~~l o c~o c~(~~~~c cilrrc~ii.~ (24" C. I h). The insolubilizcd immune complexes were precipitated by ce~itrifu-gation at 15,000 x g for 5 min, after which prolidasc activities in the supcrnatants were nieasured.
I1oc1ro~~horc.si.r rtnd immunohlo~ting. Polyaerylamide gel electrophoresis in the presenec of NaDodS04 was performed using thc discontinuous buffer system cf Laemmli (1 7) with 5% acrylamidc for stacking gel and 10% acrylamidc for separating gel. The molecular weight markers uscd wcrc myosine (MW = 200,000), P-galactosidase ( M W = 1 16.000). phosphorylasc b (MW = 92.500), bovine serum albumin (MW = 67.000). o v o albumin (MW = 43.000). carbonic anhydrase (MW = 3 1.000). and soybean trypsin inhibitor (MW = 21,500). For immunoblotting, protcins were transferred to nitrocellulose (18). The nitrocellulosc was incubated with the antiserum (1: 100 dilution) and then pcroxidase-conjugated antirabbit immunoglobulins. Fig. 2 . Coomasic staining of thc Nal)odS04/acl-ylanlicic gel. 1 . l~ The peroxidasc was visualized by 4-methyl-1-naphthol (Aldrich clcctrophorcsis was sun using 10%' NaDodS04/acryla~~iicfc gel. as dcChemical Company, Inc., Milwaukee, WI).
scribed in "Experimental proccdurcs." Thc gel was stained \vith coomasic
G'cl/i/lrulion c.o/lrmn chroinalogr~lpli!' /i)r tno/cc.ir/ur mu.\.s c..s-
brilliant blue R-250 and dcstained. I.arrcZ (I. highly purified prcpai.ation limulion. For estimation of molecular mass of prolidasc on gel from liver ( I 5 pg). Lritrc, h. highl!, purificd preparation from erythrocytes filtration, the Supcrose column was calibrated according the ( I 5 pg). 
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* Amounts of protcln werc e5t1matcd by the absorbance at 280 nni Other assays. Prolidase activity was measured using glycyl-1,-proline as a substrate in 50 mM Tris-HCI buffer, pH 7.4 containing 10 mM MnCI2. The assay mixture was preincubated at 37" C for 30-60 min in a total volume of 200 and 50 ~1 of 0.1 M glycyl-L-proline was added to initiate the reaction. The reaction was terminated by adding 250 PI of 10% trichloroacetic acid, and the supernatant obtained after centrifugation was measured for proline by the method of Chinard (13) as described previously (19) (1 U = 1 ~rnol/min proline liberated from glycyl-L-proline). Amounts of protein were estimated by the method of Lowry et al. (20) using bovine serum albumin as standard or by absorbance at 280 nm.
RESULTS
Highly purified preparations, which were chromatographically pure on the ion exchange column (Fig. 1) and gel filtration column of HPLC, were obtained. The purifications of prolidase from liver and erythrocytes are summarized in Tables 1 and 2 , respectively. The recovery rate of prolidase was very low; perhaps partially due to the progressive decrease of specific activity of the enzyme, since repeated chromatography on HPLC sometimes results in a decrease of specific activity. The two enzymes from liver and erythrocytes could not be distinguished on HPLC with the ion exchange column and the gel filtration column. In NaDodS04/acrylamide gel electrophoresis, the highly purified preparations from liver and erythrocytes contained a major protein with MW = 56,000 and a minor one of MW = 43,000 (Fig. 2) . The relative molecular mass of prolidase was estimated on a gel filtration as MW = 97,000, for both enzyme preparations. These preparations were used for immunization of mice and rabbits, as described.
The ability of the monoclonal antibody to immunoprecipitate Fig. 4 . Immunoblotting analysis of affinity purified prolidase from liver and erythrocytes. The crude tissue extracts prepared from 0.1 g wet weight of tissues or 0.1 ml packed erythrocytes were used as starting materials (details in "Experimental procedures"). The reducing condition was prepared with 10 mM dithiotreitol in the sample buffer. Affinity purified, liver (lane a) and erythrocytes (lane b) were analyzed on NadoDS04/acrylamide gel and immunoblotting with the antiserum as described in "Experiment procedures." prolidase was tested using S. aureus coated with protein A.
Precipitation was measured by monitoring enzyme activity in the supernatant solution. As shown in Figure 3 , the antibody bound to prolidase from the erythrocytes and liver. Results of control experiments included the following: 1) prolidase activities were not precipitated with S. aureus in the absence of the mouse IgG-EP2, 2) prolidase activities were not precipitated with nonspecific mouse IgG and S. aureus. Prolidase activities in these tissue and cell extracts were not inhibited by EP-2, under the conditions described. Similar titration curves for different tissue extracts indicated that this antibody recognized equally prolidase from the liver and erythrocytes. This suggested to us that the prolidase in these tissues and cells has the same antigenicity against EP-2 and that all of the prolidase activities were associated with the antigen. When we used antiserum for immunoprecipitation, similar titration curves for liver and erythrocytes were obtained (data not shown).
To assess whether human erythrocyte prolidase from clinically normal individuals could be recognized by the antibody, numbers of peripheral blood samples were tested. In these experiments, antibody (EP-2)-coated immunoplates were used. In more than 400 blood samples analyzed, there were no cases in which Kcsults of irnmunohlottil~g alter NaI)odSO.,/ac,~-!lamicie gcl clcctrophor-c\is of attinit! pur-i1ic.d material\ 21-c she\\ n in I:~SLII.C 4. Affinit! purification had been used to cnricli proliclase. \pc'cil: icall! from crude tissue cxtr-acts. ,1pp1-o\imatcl~ I I 11 psoliria~c h o u l~d to I ml gel in this c\pe~-iment. A pr-otein ol'blLi. = 56.000 mas stained \vlicn aftinit? purified materials k o n l li\cl-allti erg thr-oc) tcr \\ere analy/cd (Fig. 4) . tile imrnunoprccipitat~on c'per'lmcllt n a s arlal!/c%tl. I IIC blLV -43.000 protein \\as visuali/cd tn \omc cxl,crimcnts \\it11 pro-longed incubation of EP-2 Sepharose and sample in the absence controls studied under identical conditions demonstrated a proof proteinase inhibitors. It is possible that the MW = 43,000 tein band of MW = 56,000. We tentatively conclude that the protein, which is found in the highly purified preparations, is a protein of MW = 56,000 was a subunit of erythrocyte prolidase protcolytic product of the MMI = 56,000 protein. However, our and that this subunit was absent in the erythrocytes of the patient experiments did not exclude the possibility that the MW = with prolidase deficiency. 43,000 protein is an unrelated protein. It was suggested that MW = 56,000 protein was a subunit of prolidase in the erythrocytes DISCUSSION and in the liver.
To study whether immunologically cross-reactive material was included in the hemolysate from a prolidase-deficient patient (prolidase activity was not detected in hemolysate), competition experiments were carried out in which prolidase from 10 F1 of packed erythrocytes were immunoprccipitated in the presence or absence of 100 of the same fraction from the patient's peripheral blood. Immunoprecipitations of prolidase from the control by EP-2 and antiserum were not inhibited when the hemolysate from the patient was included in the immunoprecipitation mixtures (Fig. 5, A and B) . These results suggested the absence of immunologically cross-reactive material in the hemolysate from the patient.
The crude extract from the erythrocytes of a prolidase deficient-patient did not yield any positively stained band when analyzed by immunoblotting (Fig. 6 ). Erythrocytes of five healthy Fig. 6 . Immunoblotting analysis of affinity purified prolidase from hemolysates of control and prolidase-deficient subjects. The samples were prepared and analyzed as described in "Experimental procedures". For each lane, 30 mg protein was used as a starting material. Immunoblotting was performed with the antiserum. Lunc a. crude extract from a patient's erythrocytes was treated with EP-2 Sepharose; lane b, control sample was treated with EP-2 Sepharose; lane c, crude extract from a patient's erythrocytes was treated with nonspecific mouse IgG Sepharose; lrined, control sample was treated with nonspecific mouse IgG Sepharose This may be the first report concerning an immunochemical analysis of prolidase and prolidase deficiency. Although purification studies ofprolidase in porcine (7) and bovine (10) intestine have been described, the knowledge of human prolidase is limited and apparently the only purification study published has been our earlier report (9). To understand this enzyme and its deficiency more accurately, we attempted to identify the protein using a highly specific technique. For this purpose, we developed a monoclonal-monospecific antibody directed against human prolidase. Our results in this regard are clear-cut. Based on our results using the antibody EP-2 to purify 'he enzyme from crude extracts of tissues and cells, and specific antiserum to identify the enzyme protein in immunoblotting, it is apparent that the protein of MW = 56,000 is a subunit of prolidase in liver and erythrocytes. Our immunochemical analysis of hemolysate from a patient with prolidase deficiency indicates that the absence of prolidase activity is accompanied by absence of the MW = 56,000 protein. The relative molecular mass of purified enzyme from liver and erythrocytes was eztimated to be 97,000 on the gel filtration. Prolidase may be a dimer of MW = 56,000 subunit. The relative molecular mass of human prolidase is similar to that of bovine intestine enzyme (lo), which exists as a dimer. The mass of the subunit of the human enzyme was coincided with that of the bovine enzyme (10).
We demonstrated that prolidase in the liver and in the erythrocytes could not be distinguished by immunochemical analysis. Clinical observations on patients with prolidase deficiency suggest that the enzyme deficiency involves many organs (2, 21) , and one can assume that the structural gene for prolidase is identical in many organs.
Our initial interest in developing these studies was in identifying factors that could be involved in the expression of prolidase deficiency. In this regard, our experiments clearly indicate that a defect in the subunit of prolidase is a cause of prolidase deficiency. Further immunochemical analysis of prolidase in prolidase-deficient patients with various degrees of residual activity has to be done. Clinical features of the disorder are not always related to the degree of enzyme deficiency, and genetic heterogeneity of prolidase deficiency may be demonstrable by the immunochemical analysis. Another aspect of this study is providing useful antibodies for further understanding of prolidase and its genetics. This monoclonal antibody can be used for rapid purification of human prolidase.
